Immuneering has reported updated data on atebimetinib in first-line pancreatic cancer patients, linking the MEK inhibitor to 64% overall survival at 12 months.

Long-term data suggest Moderna’s personalized melanoma shot provides “durable tumor control,” one analyst said. Elsewhere, ...

US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of more than $20bn in what would be the latest big deal in the red-hot ...

Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...

PRINCETON, N.J., July 10, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune ...

Lehi, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Lehi, Utah, September 3, 2025 – CancerVax, Inc., the developer of a breakthrough universal cancer treatment platform that uses the body’s immune system to ...

Amgen has bought cancer biotech Dark Blue Therapeutics in a deal that could be worth as much as $840mn, marking the latest purchase of a UK-based company by a US pharmaceutical group.

Pelareorep plus atezolizumab achieves 30% ORR in second-line or later (≥2L) squamous cell anal carcinoma (SCAC) relative to 13.8% for the FDA-approved 2L treatment The median duration of response was ...

Johnson & Johnson plans to acquire clinical-stage biotech Halda Therapeutics OpCo. Inc. in a deal worth $3.05 billion. The New Brunswick-based pharma giant announced the agreement Nov. 17. The move ...

If treating cancer is like waging a war inside a patient's body, chemotherapy can be compared to a carpet-bombing campaign. The treatment usually destroys everything in its path, killing healthy and ...

Biotech headwinds are driving double-digit revenue growth and profitability for these two mid-caps.